Patents Examined by Avis Davenport
  • Patent number: 6043221
    Abstract: The present invention relates generally to methods for preventing and/or treating injury or degeneration of cochlear hair cells and spiral ganglion neurons by administering a neurturin neurotrophic factor protein product. The invention relates more specifically to methods for treating sensorineural hearing loss.
    Type: Grant
    Filed: June 29, 1998
    Date of Patent: March 28, 2000
    Assignee: Amgen Inc.
    Inventors: Ella Magal, John M. Delaney
  • Patent number: 5238919
    Abstract: This invention provides a peptide fragment of human von Willebrand Factor (vWF) and sub-fragment thereof isolated as enzymtic digestion products from naturally occurring human vWF, or isolated from synthetic peptide mixtures or isolated from lysates of organisms capable of producing recombinant human vWF. The fragments and sub-fragments are useful in the prevention and treatment of cardiovascular disorders by virtue of their ability to inhibit the binding of vWF to platelets, heparin and/or collagen.
    Type: Grant
    Filed: May 7, 1990
    Date of Patent: August 24, 1993
    Assignee: Scipps Clinic and Research Foundation
    Inventors: Theodore S. Zimmerman, Yoshihiro Fujimura, Richard A. Houghten, Zaverio M. Ruggeri
  • Patent number: 5190918
    Abstract: Compounds and compositions comprising fragments and synthetic analogs of human thrombospondin are provided together with methods for their use as thrombospondin-like agents.
    Type: Grant
    Filed: February 22, 1990
    Date of Patent: March 2, 1993
    Assignees: W. R. Grace & Co.-Conn., The Medical College of Pennsylvania
    Inventors: Alan H. Deutch, George Tuszynski
  • Patent number: 5171838
    Abstract: Compositions comprising peptide analogues of a CD4 epitope capable of interacting with a monoclonal antibody designated Leu3a or with the envelope glycoprotein (gp120) of the human immunodeficiency virus (HIV) are provided. In a preferred embodiment, the peptide will consist of the amino acid sequence: ser-lys-leu-asn-asp-arg-ala-asp-ser-arg-arg-ser-leu-trp-asp. The invention also includes a series of peptides having one or more D-amino acid substitution that confer enhanced resistance to degradation in serum. Pharmaceutical compositions and methods for using the peptides in therapeutic applications are also provided.
    Type: Grant
    Filed: May 22, 1990
    Date of Patent: December 15, 1992
    Assignee: Kureha Kagaku Kogyo Kabushiki Kaisha
    Inventor: Yukinobu Chiba
  • Patent number: 5157020
    Abstract: Disclosed herein is a synthetic senescent cell antigen comprised of purified peptides immunoreactive with antibodies to the naturally occurring antigen. Preferably, the synthetic senescent cell antigen comprises two peptides with the amino acid sequences SKLIKIFQDHPLQKTYN and LFKPPKYHPDVPYVKR, respectively. The antigen and peptides may be used in compositions, diagnostic kits, and methods for detecting or measuring antibodies to senescent cell antigen, studying cellular aging and autoimmune mechanisms, separating anions from a gas or liquid, or treating certain diseases.
    Type: Grant
    Filed: May 24, 1990
    Date of Patent: October 20, 1992
    Assignee: Research Corporation Tech., Inc.
    Inventors: Marguerite M. B. Kay, John J. Marchalonis
  • Patent number: 5155209
    Abstract: The R-(+) enantiomeric form of .+-. racemic 7-(2, 3-empoxypropoxy) actinomycin D (EPA) is provided which is effective in the therapeutic treatment of cancer. The analogue has the formula: ##STR1## wherein the P's are: ##STR2## The enantiomeric form is uniformly superior to other forms of the compound in treating malignant tumors.
    Type: Grant
    Filed: August 19, 1991
    Date of Patent: October 13, 1992
    Assignee: Trustees of Boston University
    Inventor: Sisir Sengupta
  • Patent number: 5128448
    Abstract: The invention is directed to novel CCK analogs wherein Tryptophan and/or Phenylalamine are substituted with a radical which provides enhanced appetite suppressant activity to the peptide.
    Type: Grant
    Filed: January 10, 1990
    Date of Patent: July 7, 1992
    Assignee: Hoffman-La Roche Inc.
    Inventors: Waleed Danho, David J. Nelson, Gary L. Olson, Shian-Jan Shiuey, Jefferson W. Tilley, Rolf Wagner
  • Patent number: 5110795
    Abstract: Methods and compositions for the treatment of inflammatory bowel diseases, chemically-induced irritation and inflammation, and other irritative or inflammatory conditions utilizing the peptide sequences Asp-Ser-Asp-Pro-Arg, Asp-Ser-Asn-Pro-Arg, or derivatives or salts thereof are disclosed.
    Type: Grant
    Filed: January 26, 1990
    Date of Patent: May 5, 1992
    Assignee: Immunetech Pharmaceuticals
    Inventor: Gary S. Hahn
  • Patent number: 5106954
    Abstract: Erythropoietin (EPO) peptides and the use thereof for preparing epitope-specific anti-EPO antibodies are described. Also described are corresponding anti-EPO antibodies which take the form of polyclonal antibodies (antisera) or of monoclonal antibodies. These antibodies are suitable for purifying EPO, EPO derivatives or EPO peptides. The epitope-specific anti-EPO antibodies according to the invention can also be used for the detection of EPO and, in particular, for the epitope-specific detection of EPO. Additionally described are anti-idiotype antibodies which imitate a receptor region of EPO. Finally, pharmaceuticals which contain the said EPO peptides, anti-EPO antibodies or anti-idiotype antibodies, and diagnostic aids for the detection of EPO or of anti-EPO antibodies, are described.
    Type: Grant
    Filed: July 24, 1990
    Date of Patent: April 21, 1992
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Mathias Fibi, Werner Stuber
  • Patent number: 5087615
    Abstract: Disclosed are novel methods for inducing human ovulation by administering sequentially a plurality of recombinant FSH preparations, each of which have a distinguishable plasma half-life.
    Type: Grant
    Filed: March 17, 1989
    Date of Patent: February 11, 1992
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventor: Scott C. Chappel
  • Patent number: 5082926
    Abstract: A polypeptide having the following formula is provided: gly-val-lys-gly-asp-lys-gly-asn-pro-gly-trp-pro-gly-ala-pro which has the ability to promote cellular adhesion, spreading the motility, while remaining highly cell specific. Medical applications such as chemodiagnostic and chemotherapeutic devices are also provided.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: January 21, 1992
    Assignee: Regents of the University of Minnesota
    Inventors: Mary K. Chelberg, Photini-Effie C. Tsilibary, James B. McCarthy
  • Patent number: 5081107
    Abstract: The invention releates to a polypeptide of formula IR.sup.1 --CO--A.sup.1 --A.sup.2 --A.sup.3 A.sup.3 --A.sup.4 --A.sup.5 --A.sup.6 --Qwherein each of the generic terms is disclosed in full in the specification and includesR.sup.1 is a 5- or 6-membered unsaturated heterocyclic ring which contains one, two or three nitrogen atoms, which ring may optionally bear one or two substituents; a.sup.1 is a direct link to A.sup.2 ; or is His or D-His; A.sup.2 is Trp or MeTrp; A.sup.3 is Ala or MeAla; A.sup.4 is Val; A.sup.5 is Gly or D-Ala; A.sup.6 is His or Lys(Z); and Q is a group of the formula --A.sup.7.R.sup.2 in which A.sup.7 is Leu or LeMeu and R.sup.2 is hydroxy, amino, (1-3C)alkylamino or (1-3C)alkoxy; or Q is (1-6C)alkoxy or (1-10C)alkylamino.The compounds possess antagonist properties against bombesin-like peptides and are of value in treatment of malignant disease in warm-blooded animals.
    Type: Grant
    Filed: June 6, 1989
    Date of Patent: January 14, 1992
    Assignee: Imperial Chemical Industries PLC
    Inventors: Ronald Cotton, Anand S. Dutta
  • Patent number: 5071835
    Abstract: Disclosed herein are peptides of the formulaY--R.sup.1 --R.sup.2 --R.sup.3 --R.sup.4 --R.sup.5 --R.sup.6 --Zwherein R.sup.1 to R.sup.5 are designated amino acid residues; R.sup.6 is Phe, homoPhe or an amino acid residue derived from 2-amino-3-cyclohexylpropionic acid, 2-amino-3-(4-(lower alkoxy)phenyl) propionic acid or 2-amino-3-(4-halophenyl)propionic acid; Y is Phe, desamino-Phe, (lower alkanoyl)-Phe, p-haloPhe, Tyr, desamino-Tyr or (lower alkanoyl)-Tyr, or Y is the decapeptide radical W--Val--R.sup.7 --Ser--R.sup.8 --R.sup.9 --Thr--Glu--R.sup.10 --Ser--Phe wherein W is hydrogen or lower alkanoyl and R.sup.7 to R.sup.10 are designated amino acids residues, or Y is a fragment of the decapeptide radical wherein from one to nine of the amino acid residues (i.e. Val to Ser) may be deleted serially from the amino terminus of the decapeptide radical; and Z is hydroxy, amino, lower alkylamino or di(lower alkyl)amino.
    Type: Grant
    Filed: February 1, 1990
    Date of Patent: December 10, 1991
    Assignee: Bio-Mega Inc.
    Inventors: Yvan Guindon, Pierre Lavallee, Sumanas Rakhit, Gregory P. Cosentino
  • Patent number: 5070187
    Abstract: A unique class of vasopressin analogue antagonists is provided which have the pharmacological property in-vivo to antagonize pressor (V.sub.1) and/or antidiuretic (V.sub.2) activities. The chemical modifications to the vasopressin 9 member chain sequence at the no. 1, 2, and 4 positions yield a class of potent analogue antagonists which may be employed therapeutically to treat hypertension, congestive heart failure, various edematous situations, and a variety of symptoms due to inappropriate vasopressin secretion.
    Type: Grant
    Filed: November 3, 1989
    Date of Patent: December 3, 1991
    Assignee: Trustees of Boston University
    Inventors: Haralambos Gavras, Bernard Lammek
  • Patent number: 5068222
    Abstract: The invention relates to a polypeptide of formula I:R.sup.1 -A.sup.1 -A.sup.2 -A.sup.3 -A.sup.3 -A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.9 -Qwherein each of the generic terms is disclosed in full in the specification and includes: R.sup.1 is (2-6C)alkanoyl or (1-4C)alkoxycarbonyl; A.sup.1 is a direct link to A.sup.2, or is Gly or Arg; A.sup.2 is a direct link to A.sup.3, or is Gly or Pro; A.sup.3 is a direct link to A.sup.4, or is Lys or Lys(Z); A.sup.4 is His or D-His; A.sup.5 is Trp or MeTrp; A.sup.6 is Ala or MeAla; A.sup.7 is Val or MeVal; A.sup.8 is Gly or Sar; A.sup.9 is His or MeHis; and Q is a group of the formula -A.sup.10.R.sup.2 in which A.sup.10 is Leu or D-Leu and R.sup.2 is hydroxy, amino, (1-3C)alkylamino or (1-3C)alkoxy; or Q is (1-6C)alkoxy or (1-10C)alkylamino; provided that when R.sup.1 is acetyl and -A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -A.sup.9 -Q is -His-Trp-Ala-Val-Gly-His-Leu-NH.sub.2 then -A.sup.1 -A.sup.2 -A.sup.3 - is not a direct link to His.
    Type: Grant
    Filed: November 1, 1988
    Date of Patent: November 26, 1991
    Assignee: Imperial Chemical Industries PLC
    Inventors: Roger Camble, Ronald Cotton, Anand S. Dutta, Christopher F. Hayward
  • Patent number: 5068221
    Abstract: A treatment to alleviate the debilitating symptoms of motility disorders including the functional bowel diseases. Treatment of patients with analogs of GnRH significantly reduces or elmininates the symptoms of motility disorders, including bowel disease.
    Type: Grant
    Filed: May 9, 1989
    Date of Patent: November 26, 1991
    Inventor: John R. Mathias
  • Patent number: 5064939
    Abstract: Peptides which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount of such GnRH antagonists prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. These peptides may be used to treat steroid-dependent tumors, such as prostatic and mammary tumors. The peptides include cyclic, bicyclic and tricyclic analogs of the decapeptide GnRH, and preferably there are at least two covalent bonds between the residues in the 4- and 10-positions, the residues in the 5- and 8-positions and the residues in the 1- and 3-positions, respectively. Examples of such bonds include a disulfide linkage between Cys residues, an amide linkage between a side chain amino group and a side chain carboyxl group, a dicarba linkage between side-chain alkyl groups, and a carba linkage between a side-chain alkyl group and a side-chain sulfhydryl group.
    Type: Grant
    Filed: February 6, 1990
    Date of Patent: November 12, 1991
    Assignee: The Salk Institute for Biological Studies
    Inventors: Jean E. F. Rivier, Steven C. Koerber, Arnold T. Hagler, Catherine L. Rivier, Wylie W. Vale, Jr.
  • Patent number: 5055450
    Abstract: The invention concerns pharmaceutically useful trifluoromethyl ketone substituted di-, tri- and tetra-peptide derivatives of the formulae Ia, Ib, Ic set out hereinafter, and salts thereof, which are inhibitors of human leukocyte elastase. Also described herein are pharmaceutical compositions containing a peptide derivative and processes and intermediates for use in the manufacture of the peptide derivatives.
    Type: Grant
    Filed: March 13, 1990
    Date of Patent: October 8, 1991
    Assignee: ICI Americas Inc.
    Inventors: Philip D. Edwards, John A. Schwartz, Mark M. Stein, Diane A. Trainor, Richard A. Wildonger
  • Patent number: 5047502
    Abstract: Small cell lung carcinoma cells (SCLC) contain gastrin releasing peptide (GRP) receptors. The response of the cells to GRP is rapid growth. We have found a group of heptapeptides that act as GRP antagonists by blocking the binding of GRP to its receptor thereby inhibiting the growth of cells that are sensitive to the growth promoting acitivity of GRP.
    Type: Grant
    Filed: August 3, 1989
    Date of Patent: September 10, 1991
    Assignee: Merck and Co., Inc.
    Inventors: Allen I. Oliff, David C. Heimbrook, Mark W. Riemen, Victor M. Garsky
  • Patent number: 5045530
    Abstract: A pharmaceutical preparation is disclosed which is made up of a micelle or a vesicle each consisting of a cationic tenside with a monovalent ion and a hydrophobic cyclic or linear peptide, dispersed in a solvent whose pH value lies between pH 7-pH 8, the critical micellization concentration (cmc) lying in the range of 1.0.10.sup.-7 to 7.0.10.sup.-5 mol/liter. The preparations disclosed have in particular the advantage that by the increasing of the hydrophobicity of the alkyl or aryl chain or the radical at the N.sup.+ tenside both the membrane permeability is increased and furthermore the pharmaceutical active substance, in particular linear and cyclic tyrocidines (A-J), can be transferred actively into the cytosol. They thus act on the transciption level. In addition, linear and cyclic tyrocidines in particular have antiviral effects.
    Type: Grant
    Filed: April 27, 1989
    Date of Patent: September 3, 1991
    Assignee: Medici Chem.-Pharm. Fabrik Putter GmbH
    Inventor: Henrich H. Paradies